Zaprinast, a phosphodiesterase type-5 inhibitor, alters paced mating behavior in female rats

• DOI: 10.1016/j.physbeh.2008.10.013
• Publication Date: 2008-10-30T08:08:42Z
• Authors: Ann S. Clark; Sarah H. Meerts; Fay A. Guarraci
• Keywords: Male; Time Factors; Maximum Tolerated Dose; Purinones; Phosphodiesterase Inhibitors; Ovariectomy; Estrogens; Mating Preference, Animal; Rats; Sexual Behavior, Animal; 03 medical and health sciences; 0302 clinical medicine; Reaction Time; Animals; Female; Rats, Long-Evans; Progestins; Progesterone

Nitric oxide (NO) is the primary mediator of blood flow in female genital tissues and drugs that enhance the activity of nitric oxide, such as phosphodiesterase type-5 (PDE-5) inhibitors, increase vaginal blood flow in anesthetized rats. The goal of the present study was to test the effects of one PDE-5 inhibitor, zaprinast, on the display of sexual behaviors in gonadectomized, estrogen- and progesterone-treated female rats. Experiment 1 demonstrates that zaprinast alters paced mating behavior by lengthening the contact-return latency to ejaculation; there is a significant relationship between dose of zaprinast (range 1.5-6 mg/kg) and contact-return latency to ejaculation. Experiment 2 illustrates that zaprinast has no effect on preference for an intact male as measured in a No Contact partner preference test. Rats receiving zaprinast tend to exhibit reduced locomotor activity in both experiments. Collectively, these findings demonstrate that modulation of the NO-cGMP pathway using a PDE-5 inhibitor alters the display of paced mating behaviors in rats.